# Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

> **NCT00055432** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company**

## Conditions studied

- Ovarian Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Gemzar and Alimta

## Key facts

- **NCT ID:** NCT00055432
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2006-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055432, "Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00055432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*